Current Advances and Travails in Islet Transplantation

The successful demonstration that insulin-producing β-cells can be isolated (in the form of cell clusters called islets containing β and other endocrine and nonendocrine cells) from a recently deceased donor's pancreas, then transplanted into subjects with type 1 diabetes, and thereby restore, at least temporarily, insulin-independent normoglycemia has firmly established the important “proof of concept.” Even so, worldwide efforts to advance the therapy for widespread applicability have served to focus attention on the hurdles yet to clear. This review will briefly describe the present state of the art and succinctly define the research problems being attacked along with some recent advances that demonstrate significant progress. Since Paul Lacy's early rodent experiments in the 1960s established that pancreatic islets could be isolated from one animal and transplanted into a diabetic recipient to restore normoglycemia (1), investigators have pursued efforts to develop the therapy for clinical use. After years of development in various animal models and efforts to improve human islet isolation techniques (see [2–4] for reviews with a historical perspective), the first patient achieving short-term insulin independence was reported by the group at Washington University in St. Louis. That advance was based on new islet isolation technology utilizing islets pooled from several donors, intensive insulin treatment in the peritransplant period, and induction immunosuppression with antithymocyte globulin (ATG) to avoid glucocorticoid therapy (5). The development of new immunosuppressive drugs that allowed patients to remain off glucocorticoid therapy while awaiting subsequent islet infusions (because most recipients require islets from two or more donors) enabled the group in Edmonton to optimize the clinical islet transplantation procedure (6). The approach allowed the group to conclude that about 12,000 islet equivalents per recipient body weight (in kilograms) was required to restore insulin-independent normoglycemia (6) and sparked intense international interest and effort. Current …

[1]  M. Trucco,et al.  Endoscopic Gastric Submucosal Transplantation of Islets (ENDO‐STI): Technique and Initial Results in Diabetic Pigs , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  B. Hirshberg Implications of the 2008 update from the collaborative islet transplant registry , 2009, Current diabetes reports.

[3]  C. Mathieu,et al.  Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients , 2009, Diabetes.

[4]  C. Mathieu,et al.  Graves Hyperthyroidism After Stopping Immunosuppressive Therapy in Type 1 Diabetic Islet Cell Recipients With Pretransplant TPO Autoantibodies , 2009, Diabetes Care.

[5]  James M. Wilson A History Lesson for Stem Cells , 2009, Science.

[6]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[7]  D. Roelen,et al.  Allograft‐Specific Cytokine Profiles Associate with Clinical Outcome After Islet Cell Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  P. Chaffanjon,et al.  Long‐Term Survival of Nonhuman Primate Islets Implanted in an Omental Pouch on a Biodegradable Scaffold , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  C. Mathieu,et al.  Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation , 2008, Clinical and experimental immunology.

[10]  B. Hering,et al.  2008 Update From the Collaborative Islet Transplant Registry , 2008, Transplantation.

[11]  G. Szot,et al.  Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice , 2008, Proceedings of the National Academy of Sciences.

[12]  B. Hering,et al.  Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  Johnny Ludvigsson,et al.  GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.

[14]  M. Bhasin,et al.  Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice , 2008, Proceedings of the National Academy of Sciences.

[15]  N. Chao Faculty Opinions recommendation of In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. , 2008 .

[16]  Douglas A. Melton,et al.  In vivo reprogramming of adult pancreatic exocrine cells to β-cells , 2008, Nature.

[17]  Takashi Aoi,et al.  Generation of Pluripotent Stem Cells from Adult Mouse Liver and Stomach Cells , 2008, Science.

[18]  B. Alizadeh,et al.  Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation , 2008, PloS one.

[19]  E. Bonifacio,et al.  Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. , 2008, The Journal of clinical investigation.

[20]  Christophe Magnan,et al.  mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes , 2008, Diabetes.

[21]  E. Kroon,et al.  Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo , 2008, Nature Biotechnology.

[22]  J. Permert,et al.  Intramuscular Autotransplantation of Pancreatic Islets in a 7‐Year‐Old Child: A 2‐Year Follow‐Up , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  W. Uhl,et al.  Partial Pancreatectomy in Adult Humans Does Not Provoke β-Cell Regeneration , 2008, Diabetes.

[24]  C. Ricordi,et al.  Allosensitization of Islet Allograft Recipients , 2007, Transplantation.

[25]  C. Ricordi,et al.  Rapamycin Impairs In Vivo Proliferation of Islet Beta-Cells , 2007, Transplantation.

[26]  W. Sanger,et al.  Producing primate embryonic stem cells by somatic cell nuclear transfer , 2007, Nature.

[27]  A. M. Shapiro,et al.  High Risk of Sensitization After Failed Islet Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  Gao Huang,et al.  Human Islets Derived From Donors After Cardiac Death Are Fully Biofunctional , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  H. Rilo,et al.  The pancreas as an islet transplantation site. Confirmation in a syngeneic rodent and canine autotransplant model. , 2007, JOP : Journal of the pancreas.

[30]  D. Melton,et al.  Recovery from diabetes in mice by β cell regeneration , 2007 .

[31]  R. Jordan,et al.  Interference with Tissue Factor Prolongs Intrahepatic Islet Allograft Survival in a Nonhuman Primate Marginal Mass Model , 2007, Transplantation.

[32]  O. Korsgren,et al.  Effects of Immunosuppressive Drugs on In Vitro Neogenesis of Human Islets: Mycophenolate Mofetil Inhibits the Proliferation of Ductal Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  D. Melton,et al.  Recovery from diabetes in mice by beta cell regeneration. , 2007, The Journal of clinical investigation.

[34]  D. Harlan,et al.  T cell–directed therapies: lessons learned and future prospects , 2007, Nature Immunology.

[35]  Yuichiro Yamada,et al.  Follow-up Study of the First Successful Living Donor Islet Transplantation , 2006, Transplantation.

[36]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[37]  G. Camussi,et al.  Antiangiogenic and Immunomodulatory Effects of Rapamycin on Islet Endothelium: Relevance for Islet Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  E. Kroon,et al.  Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells , 2006, Nature Biotechnology.

[39]  P. van Endert,et al.  HLA Class I Epitope Discovery in Type 1 Diabetes , 2006, Annals of the New York Academy of Sciences.

[40]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[41]  J. Neilson,et al.  Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function , 2006, Nature.

[42]  N. Zhang,et al.  Sirolimus Is Associated With Reduced Islet Engraftment and Impaired β-Cell Function , 2006, Diabetes.

[43]  U. Christians,et al.  Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates , 2006, Nature Medicine.

[44]  G. Korbutt,et al.  Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways , 2006, Nature Medicine.

[45]  J. Neilson,et al.  Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. , 2006, Nature.

[46]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes , 2005 .

[47]  C. Paties,et al.  Minimal Focal Steatosis of Liver after Islet Transplantation in Humans: A Long-Term Study , 2005, Cell transplantation.

[48]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Hunkeler,et al.  Islet Auto‐Transplantation into an Omental or Splenic Site Results in a Normal Beta Cell but Abnormal Alpha Cell Response to Mild Non‐Insulin‐Induced Hypoglycemia , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[50]  C. Ricordi,et al.  Islet Transplantation in Type 1 Diabetes Mellitus Using Cultured Islets and Steroid‐Free Immunosuppression: Miami Experience , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  D. Roelen,et al.  Alloreactivity Against Repeated HLA Mismatches of Sequential Islet Grafts Transplanted in Non-Uremic Type 1 Diabetes Patients , 2005, Transplantation.

[52]  C. Ricordi,et al.  Peripheral Blood Cytotoxic Lymphocyte Gene Transcript Levels Differ in Patients with Long-Term Type 1 Diabetes Compared to Normal Controls , 2005, Cell transplantation.

[53]  A. Shapiro,et al.  Five-year follow-up after clinical islet transplantation. , 2005, Diabetes.

[54]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[55]  K. Ekdahl,et al.  Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. , 2005 .

[56]  B. Hering,et al.  Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. , 2005, JAMA.

[57]  N. Mueller,et al.  Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience , 2005, Nature Medicine.

[58]  R. Bottino,et al.  Response of human islets to isolation stress and the effect of antioxidant treatment. , 2004, Diabetes.

[59]  D. Harlan,et al.  Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. , 2004, The Journal of clinical investigation.

[60]  C. Ricordi,et al.  Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. , 2004, Diabetes.

[61]  C. Greenbaum,et al.  Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[62]  A. Shapiro,et al.  Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. , 2004, Diabetes.

[63]  R. Robertson Islet transplantation as a treatment for diabetes - a work in progress. , 2004, The New England journal of medicine.

[64]  Mark Peakman,et al.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. , 2004, The Journal of clinical investigation.

[65]  J. Bluestone,et al.  Beta-cell replacement for type I diabetes. , 2004, Annual review of medicine.

[66]  C. Ricordi,et al.  Twenty years of clinical islet transplantation at the Diabetes Research Institute--University of Miami. , 2004, Clinical transplants.

[67]  D. Harlan,et al.  Survival after pancreas transplantation in patients with diabetes and preserved kidney function. , 2003, JAMA.

[68]  U. Johansson,et al.  Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. , 2003, Biochemical and biophysical research communications.

[69]  T. Starzl,et al.  Production of alpha 1,3-galactosyltransferase-deficient pigs. , 2003, Science.

[70]  K. Ekdahl,et al.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation , 2002, The Lancet.

[71]  S. H. A. Chen,et al.  Production of α1,3-Galactosyltransferase-Deficient Pigs , 2002, Science.

[72]  J. Killestein Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[73]  J. Gaglia,et al.  Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. , 2002, Diabetes.

[74]  K. Ekdahl,et al.  Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. , 2002, Diabetes.

[75]  E. Montanya,et al.  Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. , 2002, Diabetes.

[76]  M. Peppelenbosch,et al.  The Pleiotropic Effects of Tissue Factor: a Possible Role for Factor VIIa-induced Intracellular Signalling? , 2001, Thrombosis and Haemostasis.

[77]  E. Bonifacio,et al.  Autoantibody response to islet transplantation in type 1 diabetes. , 2001, Diabetes.

[78]  E. Bonifacio,et al.  Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. , 2000, Diabetes.

[79]  M. Brendel,et al.  Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[80]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[81]  D. Becker,et al.  Persistent T cell anergy in human type 1 diabetes. , 1999, Journal of immunology.

[82]  Å. Lernmark,et al.  Tolerance to kidney allograft transplanted into Type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches , 1999, Diabetologia.

[83]  G. Elgue,et al.  Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? , 1999, Diabetes.

[84]  Å. Lernmark,et al.  Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. , 1999, Diabetes.

[85]  K. Salmela,et al.  Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft , 1998, Diabetologia.

[86]  B. Hering,et al.  Progressive Islet Graft Failure Occurs Significantly Earlier in Autoantibody-Positive Than in Autoantibody-Negative IDDM Recipients of Intrahepatic Islet Allografts , 1997, Diabetes.

[87]  P. Lacy,et al.  Sensitization to HLA antigens in islet recipients with failing transplants. , 1997, Transplantation proceedings.

[88]  C. Greenbaum,et al.  Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. , 1996, Journal of immunology.

[89]  A. Weyrich,et al.  Activated platelets signal chemokine synthesis by human monocytes. , 1996, The Journal of clinical investigation.

[90]  G. Abouna,et al.  Site for unpurified islet transplantation is an important parameter for determination of the outcome of graft survival and function. , 1995, Cell transplantation.

[91]  M. Field,et al.  Effect of 15-Deoxyspergualin on Immediate Function and Long-Term Survival of Transplanted Islets in Murine Recipients of a Marginal Islet Mass , 1994, Diabetes.

[92]  J. Lakey,et al.  SURVIVAL AND FUNCTION OF PURIFIED ISLETS IN THE OMENTAL POUCH SITE OF OUTBRED DOGS , 1993, Transplantation.

[93]  T. Edgington,et al.  An Anti-Tissue Factor Monoclonal Antibody which Inhibits TF Vlla Complex Is a Potent Anticoagulant in Plasma , 1991, Thrombosis and Haemostasis.

[94]  D. Dunn,et al.  Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts , 1990, The Journal of experimental medicine.

[95]  Y. Mullen,et al.  Destruction of islet isografts by severe nonspecific inflammation. , 1990, Transplantation proceedings.

[96]  P. Lacy,et al.  Insulin Independence After Islet Transplantation Into Type I Diabetic Patient , 1990, Diabetes.

[97]  A. Gelet,et al.  Islet Cell Autoimmunity in Type I Diabetic Patients After HLA-Mismatched Pancreas Transplantation , 1989, Diabetes.

[98]  Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion , 1988, Diabetes.

[99]  J. Nerup,et al.  Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans , 1985, Allergy.

[100]  J. Rosai,et al.  The fate of intraportally transplanted islets in diabetic rats. A morphologic and immunohistochemical study. , 1978, The American journal of pathology.

[101]  P. Lacy,et al.  Transplantation of intact pancreatic islets in rats. , 1972, Surgery.

[102]  A. Imbriano [Blood coagulation]. , 1955, La Semana medica.